Nonetheless, several treatments have been approved for CTCL: The antibody‐dug conjugate brentuximab vedotin is efficacious in treatment of CD30+ CTCL subtypes.227. Here, TNFRSF8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.